Qi Zhuang
Overview
Explore the profile of Qi Zhuang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
501
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang C, Zhong L, Xu J, Zhuang Q, Gong F, Chen X, et al.
Nat Biomed Eng
. 2024 Mar;
8(5):561-578.
PMID: 38514774
Oncolytic bacteria can trigger innate immune activity. However, the antitumour efficacy of inactivated bacteria is poor, and attenuated live bacteria pose substantial safety risks. Here we show that intratumourally injected...
2.
Wang A, Chen M, Zhuang Q, Guan L, Xie W, Wang L, et al.
Front Cardiovasc Med
. 2024 Mar;
11:1371699.
PMID: 38450377
[This corrects the article DOI: 10.3389/fcvm.2023.1142721.].
3.
Zhuang Q, Kang L, Zhang B, Li Z, Li G
J Colloid Interface Sci
. 2023 Dec;
657:482-490.
PMID: 38070334
Obtaining crystalline materials with high structural stability as well as super proton conductivity is a challenging task in the field of energy and material chemistry. Therefore, two highly stable metal-organic...
4.
Wang R, Zhuang Q, Wang J, Yang M, Zhang X, Shen J
Arch Med Sci
. 2023 Dec;
19(6):1879-1888.
PMID: 38058710
Introduction: Idiopathic pulmonary arterial hypertension (IPAH) is a rare and sporadic form of pulmonary arterial hypertension (PAH), characterized by elevated pulmonary arterial resistance leading to right heart failure. However, molecular...
5.
Zhuang Q, Chao T, Wu Y, Wei T, Ren J, Cao Z, et al.
Small
. 2023 Jul;
19(46):e2303634.
PMID: 37467294
Despite the rapid development of the immune checkpoint blockade (ICB) in melanoma treatment, the immunosuppressive tumor microenvironment (TME) still hinders the efficacy of immunotherapy. Recently, using agonists to modulate the...
6.
Zhuang Q, Chen S, Xu K, Kang L, Li Z, Li G
Inorg Chem
. 2023 Jul;
62(29):11570-11580.
PMID: 37434493
With the gradual progress of research on proton-conducting metal-organic framework (MOFs), it has become a challenging task to find MOF materials that are easy to prepare and have low toxicity,...
7.
Wang A, Chen M, Zhuang Q, Guan L, Xie W, Wang L, et al.
Front Cardiovasc Med
. 2023 Jun;
10:1142721.
PMID: 37378404
Background: Many retrospective studies suggest that risk improvement may be a suitable efficacy surrogate endpoint for pulmonary arterial hypertension (PAH) medication trials. This prospective multicenter study assessed the efficacy of...
8.
Chen S, Tao L, Zhu F, Wang Z, Zhuang Q, Li Y, et al.
Heliyon
. 2023 May;
9(5):e15583.
PMID: 37153438
Abnormal bone metabolism and subsequence osteoporotic fractures are common complications of chronic inflammatory diseases. No effective treatment for these bone-related complications is available at present. The chronic inflammatory state in...
9.
Zhuang Q, Chen S, Zhang W, Gu M, Xiao L, Li Y, et al.
J Agric Food Chem
. 2022 Dec;
71(1):411-420.
PMID: 36540936
Osteoporosis (OP) is mainly manifested by bone loss and bone degeneration. OP is considered a risk factor for pathological fractures, as well as impacts the health of middle-aged and elderly...
10.
Li J, Wu Y, Xiang J, Wang H, Zhuang Q, Wei T, et al.
Chem Eng J
. 2022 Dec;
456:140930.
PMID: 36531858
Messenger RNA (mRNA) vaccines, while demonstrating great successes in the fight against COVID-19, have been extensively studied in other areas such as personalized cancer immunotherapy based on tumor neoantigens. In...